Loading...
•
Sep 30, 2024
Zevra Q3 2024 Earnings Report
Zevra reported financial results, highlighted by FDA approval of MIPLYFFA and its subsequent product launch.
Key Takeaways
Zevra Therapeutics reported a net revenue of $3.7 million for Q3 2024, driven by reimbursements from the French expanded access program for arimoclomol and royalties from the AZSTARYS® license agreement. The company's cash, cash equivalents, and investments totaled $95.5 million. The FDA approval of MIPLYFFA capsules for NPC treatment was a major milestone.
FDA approved MIPLYFFA capsules for the treatment of Niemann-Pick disease type C (NPC).
As of Oct. 31, Zevra received 90 prescription enrollment forms for MIPLYFFA, with 30% approved for reimbursement.
Zevra launched AmplifyAssist™, a support program for caregivers and those eligible living with NPC or UCDs.
Zevra is refining its commercial strategy for OLPRUVA to focus on specific patient segments.
Forward Guidance
Zevra expects its cash runway to extend into 2027, based on its current operating plan, available cash, cash equivalents, and investments, subject to continuing compliance with debt covenants.
Positive Outlook
- Anticipated revenue from MIPLYFFA sales
- Reimbursements from the French EAP
- Royalties under the AZSTARYS license agreement
- Continued investments into our development pipeline programs
- Potential proceeds from a PRV sale
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...